Skip navigation
Watchlist Sponsored By :

Current DateTime: 01:02:23 23 Nov 2008
LinksList Documentid: 24890560
  • Risk & You

      It's a risky world out there. Whether it's investment or retirement, career or home you can take steps to lower your risk profile.

  • Wall Street In Crisis

      With shock after shock to the world's financial system, the credit crunch continues to drive a major reconfiguration of the Wall Street landscape.

  • Protecting Your Portfolio

      Credit Crunch. Recession. Bear Market. There's a triple threat out there for investors. Here's a guide to managing your money.

Questions Arise Again on Vytorin Cancer Risk
By Mike Huckman, Pharmaceuticals Reporter | 02 Sep 2008 | 05:03 AM ET
Text Size

Two reports and an editorial in "The New England Journal of Medicine" are raising questions again about the potentially higher risk of death from cancer associated with a popular cholesterol-fighting drug.

An analysis of three large studies of Vytorin from Merck [MRK  Loading...      ()   ] and Schering-Plough [SGP  Loading...      ()   ] counts 134 cancer-related deaths among patients taking the drug versus 92 deaths in patients getting a placebo or the cholesterol drug Zocor.

Some experts and the companies say the higher number of fatalities is due to chance and an anomaly.

But researchers in NEJM say the difference is cause for concern and warrants further study.

In addition, a NEJM editorial says, "It is appropriate to raise a note of caution," and that doctors and patients "are left, for now, with uncertainty about the efficacy and safety of the drug."

Vytorin is a mixture of Merck's Zocor and Schering-Plough's Zetia. Vytorin and Zetia prescriptions have fallen, as well as the stock prices of Merck and Schering-Plough, since a piece of the cancer data and another study about the drugs' efficacy were released over the past several months.

Last year, the companies sold around $5 billion worth of the pills.

© 2008 CNBC.com

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC MOBILE  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis